Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Impact of Resilience, Anxiety and Depression on Quality of Life Assessment in Patients with Acute Myeloic Leukemia After Allogeneic Stem Cell Transplantation

Susanne Amler, MSc, Christian Deiters, Cristina Sauerland, MSc, Joachim Kienast, Thomas Buchner, MD, Andrea Schumacher, PhD

Blood (2011) 118 (21): 2088.

https://doi.org/10.1182/blood.V118.21.2088.2088

Published: 2011

Journal Articles

Characterization of Hematopoietic Progenitor Kinase 1 (HPK1) in Multiple Myeloma: a Player in Pathogenesis?,

Guido Bisping, Dirk Gustavus, Friedemann Kiefer, Eberhard Korsching, Joachim Kienast, Wolfgang E. Berdel

Blood (2011) 118 (21): 3956.

https://doi.org/10.1182/blood.V118.21.3956.3956

Published: 2011

Journal Articles

Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial

Blood (2011) 118 (21): 2773.

https://doi.org/10.1182/blood.V118.21.2773.2773

Published: 2011

Journal Articles

An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission

Blood (2011) 118 (21): 157.

https://doi.org/10.1182/blood.V118.21.157.157

Published: 2011

Journal Articles

Allogeneic Stem Cell Transplantation Confers a Favorable Outcome in Patients with NPM1 Positive Acute Myeloid Leukemia: Results From a Donor Vs. No-Donor Analysis of 309 Patients Treated in the SAL AML-2003 Trial

Blood (2011) 118 (21): 493.

https://doi.org/10.1182/blood.V118.21.493.493

Published: 2011

Journal Articles

A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial

Blood (2011) 118 (21): 497.

https://doi.org/10.1182/blood.V118.21.497.497

Published: 2011

Journal Articles

Anti-Myeloma Activity of LDC-000067, a Novel Selective Inhibitor of Cyclin Dependent Kinase 9: A Targeted Approach

Kathrin Niepoth, Dirk Gustavus, Doris Wenning, Michael Meisterernst, Joachim Kienast, Wolfgang E. Berdel, Guido Bisping

Blood (2011) 118 (21): 5110.

https://doi.org/10.1182/blood.V118.21.5110.5110

Published: 2011

Journal Articles

Relevance of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) On Non-Relapse Related Mortality (NRM) in Patients with Acute Lymphoblastic Leukemia (ALL) Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Complete Remission: Results From the GMALL Study Group.

Matthias Stelljes, MD, Mareike David, Renate Arnold, MD, Dietrich W Beelen, MD, Wolfgang A Bethge, MD, Martin Bornhäuser, MD, Jolanta Dengler, MD, Juergen Finke, MD, Hans J Kolb, MD, Karin Kolbe, MD, Nicolaus Kröger, MD, Dietger Niederwieser, MD, Wolf Rösler, MD, Rainer Schwerdtfeger, MD, Joachim Kienast, MD, Nicola Goekbuget, MD, Dieter Hoelzer, MD, PhD

Blood (2009) 114 (22): 3352.

https://doi.org/10.1182/blood.V114.22.3352.3352

Published: 2009

Journal Articles

Immunological Intervention Triggered by Decreasing CD34 + Lineage-Specific Donor Cell Chimerism to Prevent Relapse of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Felix Rosenow, Gerda Silling, MD, Berkemeier Almut, MD, Carsten Mueller-Tidow, MD, Steffen Koschmieder, MD, Guido Bisping, MD, Utz Krug, MD, Thomas Buechner, MD, Wolfgang E Berdel, MD, Joachim Kienast, MD, Matthias Stelljes, MD

Blood (2009) 114 (22): 3317.

https://doi.org/10.1182/blood.V114.22.3317.3317

Published: 2009

Journal Articles

Shift to a New Donor Does Not Improve the Outcome After Second Allogeneic Stem Cell Transplantation (alloSCT) in Acute Leukemia Relapse After a First Allosct – a Risk Factor Analysis by the German Stem Cell Registry (DRST).

Blood (2009) 114 (22): 3328.

https://doi.org/10.1182/blood.V114.22.3328.3328

Published: 2009

Journal Articles

Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.

Blood (2009) 114 (22): 485.

https://doi.org/10.1182/blood.V114.22.485.485

Published: 2009

Journal Articles

Older Age Is An Independent Risk Factor in AML

Blood (2008) 112 (11): 555.

https://doi.org/10.1182/blood.V112.11.555.555

Published: 2008

Journal Articles

Reduced Toxicity Conditioning with Treosulfan and Fludarabine in Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: Results of an International Prospective Phase II Trial.

Blood (2008) 112 (11): 3274.

https://doi.org/10.1182/blood.V112.11.3274.3274

Published: 2008

Journal Articles

Mesenchymal Stems Cells and Regulatory T Cells Inhibit Alloantigen Mediated Graft-Versus-Host Reaction but Also Impair Graft-Versus-Tumor Reactions Targeting Tumor Associated Antigens

Matthias Stelljes, Sarah Harmata, Verena Schlösser, Corinna Opitz, Jörn Albring, Felix Rosenow, Bülent Sargin, Wolfgang E. Berdel, Joachim Kienast

Blood (2008) 112 (11): 4613.

https://doi.org/10.1182/blood.V112.11.4613.4613

Published: 2008

Journal Articles

Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography

Matthias Stelljes, Sven Hermann, Jörn Albring, Gabriele Köhler, Markus Löffler, Christiane Franzius, Christopher Poremba, Verena Schlösser, Sarah Volkmann, Corinna Opitz, Christoph Bremer, Torsten Kucharzik, Gerda Silling, Otmar Schober, Wolfgang E. Berdel, Michael Schäfers, Joachim Kienast

Blood (2008) 111 (5): 2909–2918.

https://doi.org/10.1182/blood-2007-10-119164

Published: 2008

Includes: Multimedia, Supplemental data

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (Allo-SCT) Versus Conventional Postremission Therapy (PRT) for AML in First Complete Remission (CR1): A Matched Pairs Analysis Based on Data of the AML Cooperative Group (AMLCG) 1999 Trial.

Joachim Kienast, D.W. Beelen, H.J. Kolb, R. Schwerdtfeger, R. Arnold, A. Reichle, E. Holler, P. Staib, M.C. Sauerland, B. Berning, C. Schmid, M. Stelljes, W.E. Berdel, W. Hiddemann, T. Buchner

Blood (2007) 110 (11): 328.

https://doi.org/10.1182/blood.V110.11.328.328

Published: 2007

Journal Articles

Related Versus Unrelated Donor Transplantation for High Risk (HiRi) Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).

Joachim Kienast, Hans-Jochem Kolb, Dietrich W. Beelen, Maria Cristina Sauerland, Björna Berning, Albrecht Reichle, Ernst Holler, Renate Arnold, Karin Kolbe, Peter Staib, Rainer Schwerdtfeger, Matthias Stelljes, Christoph Schmid, Claudia Haferlach, Wolfgang E. Berdel, Wolfgang Hiddemann, Thomas Buchner

Blood (2007) 110 (11): 169.

https://doi.org/10.1182/blood.V110.11.169.169

Published: 2007

Journal Articles

Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.

Christoph Schmid, MD, Johanna Tischer, MD, Matthias Stelljes, MD, Michael Schleuning, MD, Rainer Schwerdtfeger, MD, Ute Hegenbart, MD, Joerg Schubert, MD, Wichard Vogel, MD, Berd Gruhn, MD, Christiane Lallinger, Georg Ledderose, MD, Martin Bornhaeuser, MD, Joachim Kienast, MD, Hans-Jochem Kolb, MD

Blood (2007) 110 (11): 1651.

https://doi.org/10.1182/blood.V110.11.1651.1651

Published: 2007

Journal Articles

Conditioning with 8 Gy Total Body Irradiation and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: Projected 4-Year Update.

Matthias Stelljes, MD, Martin Bornhaeuser, MD, Matthias Kroger, MD, Joerg Beyer, MD, Maria C. Sauerland, Achim Heinecke, PhD, Bjorna Berning, MD, Christian Scheffold, MD, Gerda Silling, MD, Thomas Buchner, MD, Andreas Neubauer, MD, Axel Arthur Fauser, MD, Gerhard Ehninger, MD, Wolfgang E. Berdel, MD, Joachim Kienast, MD

Blood (2006) 108 (11): 3016.

https://doi.org/10.1182/blood.V108.11.3016.3016

Published: 2006

Journal Articles

Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML).

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Claudia Schoch, MD, Torsten Haferlach, MD, Hubert L. Serve, MD, Joachim Kienast, MD, Susanne Schnittger, PhD, Wolfgang Kern, MD, Joelle Tchinda, MD, Albrecht Reichle, MD, Peter Staib, MD, Wolf-Dieter Ludwig, MD, Carlo Aul, MD, Maria Cristina Sauerland, Dipl Math, Achim Heinecke, PhD, Bernhard Josef Wormann, MD, Wolfgang Hiddemann, MD

Blood (2006) 108 (11): 1977.

https://doi.org/10.1182/blood.V108.11.1977.1977

Published: 2006

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of Resilience, Anxiety and Depression on Quality of Life Assessment in Patients with Acute Myeloic Leukemia After Allogeneic Stem Cell Transplantation

Characterization of Hematopoietic Progenitor Kinase 1 (HPK1) in Multiple Myeloma: a Player in Pathogenesis?,

Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial

An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission

Allogeneic Stem Cell Transplantation Confers a Favorable Outcome in Patients with NPM1 Positive Acute Myeloid Leukemia: Results From a Donor Vs. No-Donor Analysis of 309 Patients Treated in the SAL AML-2003 Trial

A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial

Anti-Myeloma Activity of LDC-000067, a Novel Selective Inhibitor of Cyclin Dependent Kinase 9: A Targeted Approach

Immunological Intervention Triggered by Decreasing CD34 + Lineage-Specific Donor Cell Chimerism to Prevent Relapse of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Shift to a New Donor Does Not Improve the Outcome After Second Allogeneic Stem Cell Transplantation (alloSCT) in Acute Leukemia Relapse After a First Allosct – a Risk Factor Analysis by the German Stem Cell Registry (DRST).

Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.

Older Age Is An Independent Risk Factor in AML

Reduced Toxicity Conditioning with Treosulfan and Fludarabine in Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: Results of an International Prospective Phase II Trial.

Mesenchymal Stems Cells and Regulatory T Cells Inhibit Alloantigen Mediated Graft-Versus-Host Reaction but Also Impair Graft-Versus-Tumor Reactions Targeting Tumor Associated Antigens

Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography

Allogeneic Hematopoietic Stem Cell Transplantation (Allo-SCT) Versus Conventional Postremission Therapy (PRT) for AML in First Complete Remission (CR1): A Matched Pairs Analysis Based on Data of the AML Cooperative Group (AMLCG) 1999 Trial.

Related Versus Unrelated Donor Transplantation for High Risk (HiRi) Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).

Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.

Conditioning with 8 Gy Total Body Irradiation and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: Projected 4-Year Update.

Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only